A Study to Evaluate Biomarkers in Moderate to Severe Ulcerative Colitis (UC) Patients Treated With Different Targeted Therapies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

95 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-07-28

Study Completion Date

2027-09-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

UC is a chronic, idiopathic form of intestinal inflammatory disease (IBD) that affects the colon, most commonly afflicting adults aged 30-40 years and resulting in disability and lower quality of life (1). It is characterized by relapsing and remitting mucosal inflammation, starting in the rectum and extending to proximal segments of the colon. Although biologic therapies have provided clinical benefits to patients, these goals are still poorly met, due to the limited knowledge of the underlying mechanisms of immunopathology and the lack of predictive biomarkers that would allow proper patient stratification.

The hypothesis of this study is that by identifying new biomarkers in blood, stool and tissue that (i) predict response (or non-response) to therapy prior to the start of treatment and (ii) predict response to therapy in the early phase of treatment will allow to find the right treatment for the right patient (personalized medicine).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Molecular Mechanisms of Non-response to Therapy in Patients With Inflammatory Bowel Disease

NCT05733845

Crohn's Disease Ulcerative Colitis

RECRUITING NA

IDENTIFICATION OF PROGNOSTIC AND PREDICTIVE BIOMARKERS IN INFLAMMATORY BOWEL DISEASE

NCT03809728

Inflammatory Bowel Diseases Crohn Disease Ulcerative Colitis

RECRUITING NA

Genomic/Epigenomic Biomarkers of Deregulation of Immune System in Inflammatory Bowel Diseases

NCT02878395

Crohn Disease

UNKNOWN

Research and Follow-up of the Determinants of the Progression and Complications of Inflammatory Bowel Diseases Treated or Not With Immunosuppressants.

NCT07172945

Crohn Ulcerative Colitis (UC) IBD (Inflammatory Bowel Disease)

NOT_YET_RECRUITING NA

Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis

NCT01461317

Ulcerative Colitis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis Inflammatory Bowel Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

UC patients

All patients with an established ulcerative colitis

Procedure: endoscopic biopsy

Intervention Type PROCEDURE

Per-endoscopic biopsies

Blood sampling

Intervention Type PROCEDURE

Blood sampling

stool sampling

Intervention Type PROCEDURE

stool sampling

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Procedure: endoscopic biopsy

Per-endoscopic biopsies

Intervention Type PROCEDURE

Blood sampling

Intervention Type PROCEDURE

stool sampling

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients ≥ 18 years of age (at the time of signing the ICF)
* Established diagnosis of ulcerative colitis with a minimum disease duration of 3 months
* Moderate to severe active UC defined by Mayo Score ≥ 6
* Moderate to severe active UC defined by endoscopy score of ≥2
* Indication to start any biological or small molecule agent (anti-TNF, anti- IL12/23, anti-integrin and JAK-inhibitors)
* In case of treatment with corticosteroid: stable dose for at least 3 weeks prior to baseline, dosage ≤ 20 mg prednisone
* Indication for an endoscopy for the assessment of disease activity as for standards of care and current guidelines
* Able to comply with the study procedures
* Person affiliated to or beneficiary of a social security plan
* Person informed about study organization and able to sign informed consent form

Exclusion Criteria

* Diagnosis of indeterminate colitis, microscopic colitis, ischaemic colitis, infectious colitis, radiation colitis
* Absolute contraindications to endoscopy procedures or complication during previous endoscopy
* Bleeding disorders
* Indication for surgery for UC
* Rectal topical therapy (enemas or suppositories) ≤ 2 weeks prior to baseline
* Treatment with \> 20 mg prednisone within 3 weeks prior to baseline
* Anaemia (haemoglobin \< 10 g/dl) at baseline
* Any circumstances which could contradict a study participation and lead the Investigator to assess the patient as unsuitable for study participation for any other reason
* Person referred in articles L.1121-5, L. 1121-7 and L.1121-8 of the Public Health Code:

* Pregnant, parturient or breastfeeding woman
* Minor person (non-emancipated)
* Adult person under legal protection (any form of public guardianship)
* Adult person incapable of giving consent and not under legal protection
* Person deprived of liberty for judicial or administrative decision, person under psychiatric care as referred in articles L. 3212-1 and L. 3213-1

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No